Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: Focus on antibiotic resistance

Cutis

Volumn 79, Issue 6 SUPPL., 2007, Pages 9-25

  Leyden, James J ^{a,e,f,g,h,i,j}   Del Rosso, James Q ^{b,c,d,e,f,h,i,j,k,l,m,n}   Webster, Guy F ^e,f,g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF NEVADA   (United States)

^c TOURO UNIVERSITY NEVADA   (United States)

^d The Valley Hospital   (United States)

^e Galderma Laboratories LP ^*  (United States)

^f Galderma

^g ALLERGAN INC   (United States)

^h Managed Care and Professional Affairs   (United States)

ⁱ Medicis Pharmaceutical Corporation   (United States)

^j Stiefel Laboratories Inc   (United States)

^k Coria Laboratories Ltd ^*  (Spain)

^l Intendis Inc

^m QLT Inc   (United States)

ⁿ Ranbaxy Laboratories Limited   (India)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT;

ACNE VULGARIS; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PROPIONIBACTERIUM ACNES; RESPIRATORY TRACT INFECTION; SKIN DISEASE;

ACNE VULGARIS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DERMATOLOGIC AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PROPIONIBACTERIUM ACNES; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES;

EID: 34547522958     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Webster GF. Acne vulgaris. BMJ. 2002;325:475-479.
2. Stern RS. Medication and medical service utilization for acne 1995-1998. J Am Acad Dermatol. 2000-.43: 1042-1048.
3. Leyden JJ, Marples RR, Mills OH, et al. Gramnegative folliculitis - a complication of antibiotic therapy in acne vulgaris. Br J Dermatol. 1973;88: 533-548.
4. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibioticresistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol. 2001;144:339-346.
5. Elsner P. Antimicrobials and the skin physiological and pathological flora. Curr Probl Dermatol. 2006;33: 35-41.
6. Leyden JJ. Therapy for acne vulgaris. N Engl J Med. 1997;336:1156-1162.
7. Bell DM, Drotman DP. Confronting antimicrobial resistance: a shared goal of family physicians and the CDC. Am Fam Physicians [serial online]. 1999;59:2097-2098, 2100. Available at: http://www.aafp.org/afp/99041ap/ editorials.html. Accessed August 21, 2006.
8. Bachelez H, Senet P, Cadranel J, et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137:69-73.
9. Abrutyn E. New uses for old drugs. Infect Dis Clin North Am. 1989;3:653-654.
10. Roberts DE, Curd JG. Sulfonamides as anti-inflammatory agents in the treatment of Wegener's granulomatosis. Arthritis Rheum. 1990;33:1590-1593.
11. Valeriano-Marcet J, Spiera H. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. Arch Intern Med. 1991;151:1649-1652.
12. Webster GF. Anti-inflammatory activity of antibiotics. Presented at: Scientific Panel on Antibiotic Use in Dermatology (SPAUD) Meeting; April 22-23, 2006; Las Vegas, Nev.
13. Leyden JJ. Antibiotic therapy in acne and rosacea. Presented at: Scientific Panel on Antibiotic Use in Dermatology (SPAUD) Meeting; April 22-23, 2006; Las Vegas, Nev.
14. Wolf R, Matz H, Orion E, et al. Dapsone. Dermatol Online J. 2002;8(1):2.
15. Webster GF, Alexander JC, McArthur WP, et al. Inhibition of chemiluminescence in human neutrophils by dapsone. Br J Dermatol. 1984;110:657-663.
16. Wozel G, Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol. 1995;8:196-202.
17. Modschiedler K, Weller M, Wörl P, et al. Dapsone and colchicine inhibit adhesion of neutrophilic granulocytes to epidermal sections. Arch Dermatol Res. 2000;292:32-36.
18. Ottonello L, Dapino P, Scirocco MC, et al. Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Sci (Lond). 1995;88:331-336.
19. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265.
20. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996;93:14014-14019.
21. Yrjänheikki J, Keinänen R, Pellikka M, et al. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A. 1998;95:15769-15774.
22. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139:459-464.
23. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-1441.
24. Palei AC, Zaneti RA, Fortuna GM, et al. Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology. 2005;56:611-617.
25. Sobrin L, Liu Z, Monroy DC, et al. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant, invest Ophthalmol Vis Sci. 2000;41:1703-1709.
26. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
27. Golub LM, Ciancio S, Ramamurthy NS, et al. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodont Res. 1990;25:321-330.
28. Grenier D, Plamondon P, Sorsa T, et al. Inhibition of proteolytic, serpinolytic and progelatinase-b activation activities of peridontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. J Periodontol. 2002;73:79-85.
29. Core Technologies. CollaGenex Pharmaceuticals Inc Web site. Available at: http://www.collagenex.com/core.asp. Accessed August 18, 2006.
30. O'Dell JR, Paulsen G, Haire CE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline: four-year followup of a double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42: 1691-1695.
31. Loo WJ, Kirtschig G, Wojnarowska F. Minocycline as a therapeutic option in bullous pemphigoid. Clin Dermatol. 2001;26:376-379.
32. Helm TN, Lee TC. Familial benign pemphigus (Hailey-Hailey disease). eMedicine [serial online]. Updated March 28, 2007. Available at: www.emedicine.com/derm/topicl50.htm. Accessed May 3, 2007.
33. Leyden JJ, McGinley KJ, Mills OH, et al. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol. 1975;65:382-384.
34. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte Chemotaxis. J Invest Dermatol. 1978;70:51-55.
35. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline, and erythromycin. Antimicrob Agents Chemother. 1982;21:770-772.
36. Jain A, Sangal L, Basal E, et al. Anti-inflammatory effects of erythromycin and tetracycline on Propionibacterium acnes induced production of chemotactic factors and reactive oxygen species by human neutrophils. Dermatol Online J. 2002;8(2):2.
37. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimal-inhibitory concentrations of tetracycline and erythromycin. Br J Dermatol. 1981;104:453-457.
38. Leyden JJ. The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg. 2001;20: 139-143.
39. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin, involvement of protein kinase C. Arch Dermatol. 1994;130:748-752.
40. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. Dermatology. 2003;206: 54-56.
41. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-tesistant Propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002; 146: 840-848.
42. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant Propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol. 1989;121:51-57.
43. Leyden JJ. Antibiotic resistant acne. Cutis. 1976;17: 593-606.
44. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics, Med J Aust. 1998;169:259-261.
45. Tan HH, Goh CL, Yeo MG, et al. Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. Ann Acad Med Singapore, 2001;30:22-25.
46. Dreno B, Reynaud A, Moyse D, et al. Erythromycinresistance of cutaneous bacterial flora in acne. Eur J Dermatol. 2001;11:549-553.
47. Ross JI, Snelling AM, Carnegie E, et al. Antibioticresistant acne: lessons from Europe. Br J Dermatol. 2003;148:467-478.
48. Cunliffe WJ, Holland KT, Bojar R, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24: 1117-1133.
49. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol. 1983;8:41-45.
50. Shalita AR, Myers JA, Krochmal L, et al; and Clindamycin Foam Study Group. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris, J Drugs Dermatol. 2005;4: 48-56.
51. Thiboutot D. Acne: 1991-2001. J Am Acad Dermatol. 2002;47:109-117.
52. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes. Cutis. 2001;67(suppl 2): 21-24.
53. Ellis CN, Leyden J, Katz HI, et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis. 2001;67(suppl 2): 13-20.
54. Leyden JJ. Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):51-55.
55. Shalita AR, Smith EB, Bauer E. Topical erythromycin v clindamycin therapy for acne. a multicenter, double-blind comparison. Arch Dermatol. 1984;120:351-355.
56. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49 (suppl 1):S1-S37.
57. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol. 1997;37:590-595.
58. Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol. 1992;126:586-590.
59. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006;142:597-602.
60. Leyden JJ, Thiboutot DM, Shalita AR, et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris. Arch Dermatol. 2006;142:605-612.
61. Leyden JJ, Kaidbey K, Gans EH. The antimicrobial effect in vivo of minocycline, doxycycline, and tetracycline. J Dermatolog Treat. 1996;7:223-225.
62. Solodyn [package insert]. Scottsdale, Ariz: Medicis Pharmaceutical Corporation; 2006.
63. Coates P, Vyakrnam S, Ravenscroft JC, et al. Efficacy of oral isotretinoin in the control of skin and nasal colonization by antibiotic-resistant Propionibacteria in patients with acne. Br J Dermatol. 2005;153:1126-1136.
64. Vowels BR, Feingold DS, Sloughfy C, et al. Effects of topical erythromycin on ecology of aerobic cutaneous bacterial flora. Antimicrob Agents Chemother. 1996;40: 598-604.
65. Mills O, Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Derm Venereal. 2002;82:260-265.
66. Margolis DJ, Bowe WP, Hoffstad O, et al. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol. 2005;141:1132-1136.
67. Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139:467-471.
68. Adams SJ, Cunliffe WJ, Cooke EM. Long-term antibiotic therapy for acne vulgaris: effects on the bowel flora of patients and their relatives. J Invest Dermatol. 1985;85: 35-37.
69. Miller YW, Eady EA, Lacey RW, et al. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother. 1996;38:829-837.